Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biohaven Readies Glutamate Modulator BHV-0223 For Phase III In Anxiety

Executive Summary

Glutamate modulators could play a role in a range of central nervous system disorders, including social anxiety, amyotrophic lateral sclerosis. Biohaven's first – a reformulation of a generic ALS drug – could be on the market in two years.

You may also be interested in...



Cytokinetics Sees Enough Evidence To Move Reldesemtiv Into Phase III For ALS

The Astellas-partnered drug did not reach statistical significance on any FORTITUDE-ALS endpoints, but clinically significant results over time justify a longer Phase III study that's likely to enroll ALS patients with a faster rate of disease progression.

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS

Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123711

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel